KK
CTKB icon

KLP Kapitalforvaltning’s Cytek Biosciences CTKB Stock Holding History

KLP Kapitalforvaltning’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,200
Closed -$68.7K – 2184
2025
Q2 		$68.7K Hold
20,200
– – ﹤0.01% 2118
2025
Q1 		$81K Hold
20,200
– – ﹤0.01% 2097
2024
Q4 		$131K Buy
+20,200
New +$120K ﹤0.01% 1991

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KLP Kapitalforvaltning's CTKB Position: Q3 2025 in Review

KLP Kapitalforvaltning sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 20,200 shares — an estimated $68.7K sold.

KLP Kapitalforvaltning first reported a position in CTKB in Q4 2024 and held it in 3 quarters. The position peaked at $131K in Q4 2024. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • KLP Kapitalforvaltning reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 20,200 Cytek Biosciences shares in Q3 2025, an estimated $68.7K.
  • KLP Kapitalforvaltning first reported a position in Cytek Biosciences in Q4 2024 and held it in 3 quarters.
  • KLP Kapitalforvaltning's Cytek Biosciences position peaked at $131K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2025, filed 23 Oct 2025.